Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and...

Area of Science:

• Oncology
• Radiology
• Nuclear Medicine

Background:

• Prostate cancer is a leading global malignancy requiring accurate staging and risk assessment.
• Multiparametric MRI (mpMRI) and PSMA PET have individually advanced prostate cancer diagnosis and management.
• Integrating these advanced imaging techniques offers synergistic benefits for patient care.

Purpose of the Study:

• To review the clinical utility of mpMRI and PSMA PET in prostate cancer management.
• To explore the combined application of mpMRI and PSMA PET for improved detection and staging.
• To discuss the role of integrated imaging in personalized treatment strategies.

Main Methods:

• Narrative literature review of existing studies on mpMRI and PSMA PET in prostate cancer.
• Analysis of diagnostic performance for initial diagnosis, staging, and recurrence detection.
• Evaluation of quantitative imaging biomarkers (ADC, SUV) and hybrid imaging potential.

Main Results:

• mpMRI excels in local tumor characterization, while PSMA PET is superior for detecting nodal and distant metastases.
• Quantitative biomarkers like ADC and SUV show promise for risk stratification.
• Hybrid imaging techniques can enhance diagnostic accuracy and treatment decision-making.

Conclusions:

• The integration of mpMRI and PSMA PET represents a significant advancement in precision imaging for prostate cancer.
• Combined imaging improves diagnostic accuracy, disease extent definition, and personalized management.
• This synergistic approach supports tailored therapeutic interventions, including surgery, radiotherapy, and systemic treatments.